



Published in final edited form as:

*Curr Addict Rep.* 2016 March ; 3(1): 125–137. doi:10.1007/s40429-016-0081-3.

## Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers

Daniel J.O. Roche, PhD<sup>1</sup>, Lara A. Ray, PhD<sup>1,2</sup>, Megan M. Yardley, PhD<sup>1</sup>, and Andrea C. King<sup>3</sup>

<sup>1</sup>University of California, Los Angeles, Department of Psychology, Los Angeles, CA, 90095, USA

<sup>2</sup>University of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA, 90095, USA

<sup>3</sup>University of Chicago, Department of Psychiatry and Behavioral Neuroscience, Chicago, IL 60637, USA

### Abstract

There is a strong association between cigarette smoking and alcohol use at the epidemiological, behavioral, and molecular levels, and this co-use creates substantial impediments to smoking cessation among smokers who are also heavy drinkers. Compared with individuals who only smoke, those who both drink and smoke heavily experience more severe health consequences and have greater difficulty in quitting smoking. During smoking abstinence, greater alcohol use is associated with decreased odds of smoking cessation, and smokers are substantially more likely to experience a smoking lapse during drinking episodes. As heavy drinking smokers are less responsive to the currently available pharmacological treatments, this subgroup of high-risk substance users possesses a unique clinical profile and treatment needs. Thus, treatment development for heavy drinking smokers represents a significant and understudied research area within the field of smoking cessation. This review will briefly describe findings from epidemiological, behavioral, and molecular studies illustrating alcohol and tobacco co-use and identify how the behavioral and neurobiological mechanisms underlying the interaction of alcohol and nicotine may inform the development of targeted treatments for this unique population of smokers.

### Keywords

Heavy drinking smokers; alcohol use disorder; tobacco use disorder; comorbidity; treatment; pharmacotherapy

---

*Corresponding Author:* Dr. Andrea King, Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S. Maryland Avenue (MC-3077), Chicago, IL 60637, United States. Tel.: +1 773 702 6181; fax: +1 773 702 6454. aking@bsd.uchicago.edu (A.C. King).

#### Compliance with Ethics Guidelines

#### Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

#### Conflict of Interest

Daniel Roche, Megan Yardley and Andrea King declare that they have no conflict of interest.

## 1. Introduction

Tobacco and alcohol use are among the top three leading causes of preventable disease, and contribute to nearly seven million deaths each year worldwide [1,2]. A strong link exists between cigarette smoking and alcohol use [3–5]. Co-use of these substances is associated with various negative health consequences including cancer, impaired brain structure and function, and pulmonary and cardiovascular disease [6–9]. Furthermore, beyond the risks associated with the use of each substance individually, regular alcohol and cigarette co-use synergistically increases esophageal, laryngeal, and oral cancer mortality rates [6,8,9]. In fact, more people with alcohol use disorder (AUD) die from tobacco-related than alcohol-related disease [10].

Despite the sizeable number of people who concurrently smoke and drink and the health risks that coincide with the regular co-use of these drugs, there are currently no treatments approved to reduce both alcohol consumption and cigarette consumption for this high-risk group of substance users. To reduce the health burden and prevalence of comorbid AUD and tobacco use disorder (TUD), there is a critical need to further examine existing as well as novel pharmacological agents and behavioral interventions aimed at co-use. This review will summarize findings from epidemiological, behavioral, and molecular studies on alcohol-nicotine co-use and discuss how understanding their behavioral and neurobiological mechanisms may enable further refinement of treatments for this often treatment resistant subgroup of smokers. This approach is consistent with the precision medicine initiative calling for treatments that are personalized to patient's unique risk profiles [11,12]. Furthermore, the majority of treatment development studies in heavy drinking smokers have been performed in the context of smoking cessation interventions with the exception of a retrospective analysis of alcohol treatment from the COMBINE Study [13]. This may be due to research showing that treatment for alcohol and tobacco use may produce better outcomes when delivered separately rather than simultaneously [14]. Additionally, smoking cessation is often not a priority in the treatment of AUD given the immediate health and personal consequences attributed to alcohol as opposed to the longer-term consequences caused by tobacco use. Thus, while the ultimate treatment goal for heavy drinking smokers is a reduction in both alcohol and tobacco use, this manuscript will predominantly focus on smoking cessation as the primary intervention in this subgroup. Finally, several priority areas for future clinical research on alcohol-nicotine interactions will also be discussed.

## 2. Evidence and Mechanisms of the Co-use of Alcohol and Tobacco

### 2.1 Epidemiological Findings

Alcohol and tobacco are two of the most widely abused substances and are often used in combination [15,16]. According to the National Survey on Drug Use and Health, in 2013 the rates of heavy drinking [five or more drinks on the same occasion (four or more for women) on each of five or more days in the past 30 days] and binge drinking (four drinks for women and five drinks for men in one occasion) among those aged 12 years and older in the United States were 6.3% and 22.9%, respectively, and 7.0% of those 18 years and older met the criteria for AUD [17]. In this same survey, almost a quarter (22.5%) of people aged 12 years and older reported currently using tobacco products.

Alcohol drinking levels are often higher in smokers than non-smokers, and conversely smoking levels are higher in heavy drinkers compared to non-drinkers [18]. Almost 20% of smokers engage in heavy drinking compared to about 6.5% of nonsmokers [18,19], and more than 50% of heavy drinkers aged 12 years and older reported smoking cigarettes within the past month compared with only 15.5% of people who did not consume alcohol within the past month [17]. Co-use of these substances within the same occasion is relatively common [15,20], and alcohol drinking during such bouts is often of a longer duration as compared with drinking occasions without smoking [21]. Epidemiological data shows that individuals with TUD are more likely to have AUD [22], and individuals with AUD are more likely to be smokers [23], compared with the general population. The National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions report more than 6 million adults meet the criteria for comorbid AUD and TUD [24].

As there are myriad terms for the comorbidity of AUD and TUD, we will hereto use the term “heavy drinking smokers” to describe this subgroup. Additionally, it is important to note that in studies examining heavy drinking smokers, the level of cigarette smoking (e.g., cigarettes per day) has varied substantially depending on the research questions and experimental methods employed. Laboratory studies in this area have examined a wide range of smokers, ranging from light and non-daily smokers to heavy, daily smokers while the majority of smoking cessation trials in co-users have examined heavier and daily smokers, as they are more often targeted in cessation treatment. The relatively high prevalence of heavy drinking smokers at the population level, as well as the high comorbidity of AUD and TUD, may be explained by the manner in which these drugs act synergistically to alter drug-seeking behavior.

## 2.2 Behavioral Findings from Studies in Humans

Evidence for the behavioral mechanisms underlying the relationship between alcohol and tobacco co-use has been derived from controlled human laboratory experiments as well as studies of heavy drinking smokers in their natural environment. Results from the majority of these studies suggest that the underlying motivation for co-administration of these substances is driven in part by three core psychological concepts: cue-induced craving (i.e., Pavlovian conditioning), positive reinforcement, and negative reinforcement [25–27].

In heavy drinking smokers, consumption of one substance can become a conditioned cue and subsequently induce craving for the other substance. Alcohol consumption has been consistently found to increase craving for cigarettes in the laboratory as well as in the natural environment [15,16,28–32]. Increases in smoking urges after consumption of an intoxicating dose of alcohol appear to be mediated by concomitant increases in alcohol-induced subjective stimulation but not sedation [33]. This latter finding may be particularly relevant for understanding the reciprocal relationship between alcohol and cigarette use in heavy drinking smokers, as heavy drinkers reliably report more alcohol-induced stimulation than light drinkers [34,35]. This may suggest that smoking during a drinking episode may have less to do with offsetting the sedating effects of alcohol than it is with potentiating the stimulating effects.

Though less studied, data from real-life ecological momentary assessments (EMA) suggest that cigarette smoking may also increase alcohol craving [16,36], and the co-administration of alcohol and nicotine can produce cumulatively heightened craving for both substances in the laboratory and natural environment [16,31,37]. Importantly, this substance cross-reactivity has behavioral consequences: in some, but not all, laboratory studies [38], alcohol consumption [39,40] and cigarette smoking or nicotine administration [41–43] independently increases the motivation to use, or decreases the ability to resist using, the other substance.

Alcohol consumption produces both rewarding (e.g., stimulation, tension reduction) and aversive (e.g., sedation) subjective effects [34,44]. Importantly, the magnitude and direction of alcohol's subjective effects are directly associated with motivation to consume alcohol, as greater alcohol-induced stimulation and reward is associated with increased alcohol preference and subsequent consumption [45,46], whereas heightened sedative and aversive effects, or attenuated reward, are associated with decreased consumption and preference [47,48]. Nicotine also produces stimulatory subjective effects [49,50], and individuals may co-administer alcohol and cigarettes to either amplify the rewarding effects of each drug (i.e., positive reinforcement) or alleviate the aversive effects of alcohol (i.e., negative reinforcement; [27]), which may lead to increased situational use of each substances [21].

There is laboratory evidence that cigarette and alcohol co-use may reciprocally potentiate the rewarding subjective effects of the other drug. Nicotine administration has been shown to enhance alcohol's stimulant, relaxing, euphoric, and intoxicating effects [31,49]. Additionally, alcohol increases self-reported enjoyment and satisfaction from smoking and augments the stimulating and calming effects of cigarettes [51–53]. Conversely, nicotine administration or cigarette smoking attenuates alcohol's sedating and intoxicating effects, particularly during the declining portion of the breath alcohol curve [41,49,53–55]. Nicotine also reduces alcohol's impairing effects on attention, cognition, and motor function [51,56,57]. Taken as a whole, these results suggest that alcohol and nicotine act synergistically to reinforce co-use behavior by potentiating the rewarding effects of each drug and by blunting alcohol's sedating and impairing effects. The co-reinforcement from these drugs contributes to increased cigarette and alcohol use both within a drinking session and frequency of overall use [21,58,59]. We speculate that this continued co-reinforcement over time, as well as the development of cross-tolerance to these drugs [60], underlies the development of comorbid AUD and TUD and is partly facilitated by the neurobiological overlap between these substances.

### 2.3 Molecular and Neurobiological Findings

The profile of alcohol and nicotine's additive behavioral effects suggests that the frequent co-use of these substances may be related to the overlapping pharmacological action of both drugs at the molecular level. This is supported by neuroimaging research in heavy drinking smokers showing that alcohol acutely increases activation in mesolimbic brain areas, including the ventral striatum, in response to smoking cues [61]. The preponderance of evidence suggests that the main pharmacological convergence between these substances occurs through the acetylcholine and endogenous opioid systems [62,63]. Alcohol and

nicotine affect acetylcholine activity through direct effects on nicotinic acetylcholine receptors (nAChRs) and indirectly modulate opioid transmission through both shared (i.e., nAChR activation) and independent pharmacological mechanisms. In turn, the endogenous acetylcholine and opioid systems modulate the neurocircuitry underlying addiction, including tobacco and alcohol problems [62,64–66] and the multitude of cognitive processes that can become dysfunctional in addiction, such as inhibitory control [67], working memory [68], decision-making [69], and cognitive flexibility [70].

A large amount of evidence suggests that alcohol and nicotine administration both activate nAChRs on dopamine neurons in the ventral tegmental area (VTA), thereby triggering the mesolimbic dopamine system, which is instrumental in the operant and Pavlovian learning and motivated behavior that are essential to the development of addiction [71–73]. Nicotine's direct activation of nAChRs in the VTA, particularly those containing  $\alpha 4$  and  $\beta 2$  subunits in combination with  $\alpha 6$ , is thought to be most responsible for the reinforcing effects of nicotine and development of TUD [74,75]. Furthermore, one of alcohol's primary targets is the nAChR [63], and nAChRs that contain  $\alpha 3$ ,  $\alpha 4$ ,  $\alpha 6$ ,  $\beta 2$ , and/or  $\beta 3$  subunits may contribute its reinforcing effects [66,76–79]. It has been suggested that alcohol either directly potentiates nAChRs on VTA dopamine neurons or increases the activation of cholinergic projections to these neurons [66]. Although contingent upon the order of administration, duration of exposure, and dosage [80,81], co-application of ethanol and nicotine have been shown to increase VTA dopamine neuron firing rates to a greater extent than either drug alone [82], suggesting a synergistic pharmacological interaction that parallels the behaviorally reinforcing effects of their co-use described above.

In addition to cholinergic mechanisms, the neurobiological literature has recognized a role for the endogenous opioid system in modulating responses to alcohol and nicotine [62,83]. Endogenous opioids, particularly endorphins and enkephalins, are thought to mediate the acute, rewarding effects (i.e., "liking" and other pleasurable effects) of drugs, including alcohol and nicotine [63,83,84]. Alcohol increases endorphin transmission in the nucleus accumbens and VTA, and this signaling induces dopamine release to the nucleus accumbens through independent mechanisms [85,86]. Multiple lines of evidence implicate the opioid system in both the hedonically rewarding and motivationally salient effects of alcohol [63,87]. For example, blocking alcohol-induced dopamine release and endogenous opioid action in the nucleus accumbens with opioid receptor antagonists or via  $\mu$ -opioid receptor knockout reduces alcohol self-administration and preference [88,89].

While relatively less understood, nicotine administration may also acutely increase endorphin and enkephalin release in the striatum and throughout the brain [90–92]. It has been shown that  $\mu$ -opioid receptor activity modulates nicotine's stimulation of VTA dopamine neurons [93], and  $\mu$  receptor antagonists can block nicotine's induction of the mesolimbic dopamine system [94]. Furthermore, in animal models, activation of  $\mu$ -opioid receptors mediates the rewarding effects of nicotine and incentive salience to nicotine-conditioned cues [95–97] but, in contrast to alcohol, does not appear to be involved with nicotine self-administration [98,99].

In sum, the behavioral effects of alcohol and nicotine co-administration are in part due to shared pharmacological targets in the endogenous opioid and acetylcholine systems. Our increasing knowledge of the neurocircuitry and behavioral pharmacology of alcohol and nicotine's effects suggest that nAChRs and  $\mu$ -opioid receptors may be promising molecular targets for the development of treatments for heavy drinking smokers. It should also be noted that chronic alcohol and nicotine exposure results in up-regulation of endogenous dynorphin activity, which contributes to withdrawal, negative affect, and relapse for both drugs [62,100,101]. Although the kappa-opioid system is a promising treatment target [102], there are currently no medications available clinically that are specific to kappa-opioid receptors. As such, we will focus on what is known regarding opioid system targets for treating heavy drinking smokers that focus on the mu-opioid receptor.

### 3. Treatments for AUD and TUD: Current Developments and Future Directions

#### 3.1 Challenges in Treating Alcohol and Tobacco Co-use

The treatment of heavy drinking smokers is of high clinical importance, as greater alcohol use is associated with decreased odds of smoking cessation, with smokers four times more likely to have a smoking lapse during drinking episodes than non-drinking episodes [103–106]. In early smoking abstinence, one of the greatest predictors of relapse is the occurrence of a single smoking lapse, which is generally defined as smoking at least a puff of a cigarette [107,108]. Because as many as 95% of smokers who experience a lapse will progress to relapse [108,109], the first lapse has been theorized to represent the transition from abstinence to regular smoking [110,111]. Alcohol consumption has been identified as a major risk factor for precipitating a smoking lapse: approximately 25% of smokers participating in smoking cessation trials report consuming alcohol immediately prior to a smoking lapse and identify alcohol as the predominant reason for choosing to smoke [112,113].

Given these treatment challenges and the previously discussed health concerns associated with alcohol and tobacco co-use, it has been argued that heavy drinking smokers represent a distinct and underserved sub-population of smokers based on their unique clinical profile and treatment disparities [3,114]. Although the Clinical Practice Guidelines recommend that smokers be advised to reduce or avoid drinking during a quit attempt [115], there is a paucity of support for behavioral or pharmacological treatments that have been shown to be efficacious for heavy drinking smokers [3,114]. In fact, smokers with current or past AUD have often been excluded from smoking cessation trials, thereby limiting the understanding of how to best treat this comorbid population [116]. While AUD treatment studies have not excluded smokers, the reporting of sample smoking rates, as well as cigarette quantity and frequency, as secondary outcomes has largely been ignored. Thus, treatment development for heavy drinking smokers continues to represent a highly significant and relatively understudied research area within the larger field of smoking cessation. The behavioral and molecular findings on the combined effects of alcohol and nicotine summarized earlier in this review (Sections 2.2 and 2.3) have provided mechanisms to target in treatment development. As cue-induced craving, positive reinforcement, and negative reinforcement

may be driving a significant component of alcohol and tobacco co-use, theoretically, a medication that blocks the additive rewarding effects of both substances (i.e., blocking positive and negative reinforcement), potentiates the aversive properties of either drug (i.e., blocking negative reinforcement and blunting positive reinforcement), and/or reduces reactivity to drug-conditioned cues may be particularly effective treatments for heavy drinking smokers. For example, because alcohol use commonly precedes a smoking lapse [112,113] and given that heavy drinking smokers 1) engage in a pervasive pattern of drinking behavior [34] and 2) display a heightened stimulatory response to alcohol that may be predictive of increased cigarette craving [33], heavy drinking smokers have a greater risk of experiencing a lapse, and ultimately full relapse, than lighter and non-drinking smokers [104,117,118]. Therefore, behavioral skills or a medication that helps patients reduce or abstain from drinking could conceivably aid in heavy drinking smokers' smoking quit attempts by preventing alcohol-related smoking lapses. Further, due to pharmacological evidence that alcohol and nicotine both affect nAChRs and opioid receptors, a medication targeting one or both of these systems may be ideal pharmacotherapy candidates.

### 3.2 Promising Behavioral Treatments

The few studies that have examined the effects of cognitive behavioral interventions without pharmacotherapy to reduce alcohol and cigarette co-use have shown modest results. In one randomized clinical trial, heavy drinking smokers receiving a combined brief intervention for smoking cessation and alcohol reduction showed better short-term outcomes than those receiving smoking cessation therapy, but these gains were not maintained four months after treatment [105]. Another recent pilot study showed that adding a personalized component to standard alcohol brief intervention, i.e., including feedback from a separate laboratory session demonstrating alcohol's positive effects and smoking urge increases, produced greater reductions in binge drinking frequency and alcohol-smoking co-use frequency than the standard alcohol brief intervention alone or a general health feedback attention control condition [119]. Finally, adding a population-based motivational counseling to standard smoking telephone quit lines to address limiting both alcohol and cigarette consumption produced greater rates of smoking abstinence than did the standard care smoking quit line [118]. These findings across a variety of behavioral treatments show initial promise on the efficacy and feasibility of such approaches for alcohol and tobacco co-use. More studies in this area are needed to expand this work in larger samples and also to develop and examine additional novel cognitive-behavioral approaches.

Additional approaches that specifically target the behavioral mechanisms underlying alcohol and tobacco co-use may be another promising direction. As stated previously, newer approaches to include feedback on alcohol responses, including elicitation of smoking urges, may be incorporated into existing brief interventions in young adult co-users, and adding alcohol psychoeducation in tobacco quit lines may augment outcomes in co-users attempting to quit smoking. Furthermore, recent work has shown a cognitive bias modification (CBM) technique consisting of training to alter automatic approach behaviors to drug cues produces better treatment outcomes in individuals with AUD [120]. This training may be useful in changing alcohol and tobacco approach biases in heavy drinking smokers, although no studies have been conducted to date. Overall, the Clinical Practice Guidelines for smoking

cessation suggest that pharmacological treatments be combined with psychotherapy or behavioral therapy [121], and, accordingly, most clinical trials of medications in heavy drinking smokers, but not smaller laboratory studies, have employed a combined therapy approach. We also recommend that combined behavioral and pharmacological therapies be employed in future clinical trials for heavy drinking smokers. In the next section, we specifically review research investigating various pharmacotherapies in heavy drinking smokers.

### 3.3 Promising Pharmacological Treatments

**3.3.1 Varenicline**—Recent research has focused on three promising pharmacotherapies for heavy drinking smokers, which include: varenicline (VAR), naltrexone (NTX), and the combination of VAR and low dose NTX. Varenicline tartrate is an approved treatment for TUD, and a number of recent studies have also highlighted its potential role in the treatment of AUD. As multiple clinical trials have shown that VAR is more effective than bupropion and nicotine replacement therapy as a smoking cessation agent [122–125], VAR has been advanced as a first line treatment for TUD [121]. Varenicline is a partial agonist at nAChRs containing  $\alpha 4\beta 2$ ,  $\alpha 3\beta 4$ ,  $\alpha 3\beta 2$ , and  $\alpha 6$  subunits and a full agonist at those containing  $\alpha 7$  [126,127]. Varenicline has the highest affinity for the  $\alpha 4\beta 2$ , producing ~45–70% the agonist activity and stimulating ~40–60% of VTA dopamine release of nicotine [127,128]. As previously discussed, the  $\alpha 4\beta 2$  and  $\alpha 6$  subunits appear to primarily mediate smoking reward, withdrawal symptoms, nicotine-induced neuroplasticity, conditioning, and the development of TUD [75,129–132]. Relatedly, the primary mechanisms of action of VAR are thought to stem from two primary effects. First, VAR stimulates the release of basal dopamine through activation of  $\alpha 4\beta 2$  nAChRs in the VTA, which is thought to reduce tonic nicotine craving and negative affect associated with nicotine withdrawal [16,128,133,134]. Secondly, VAR acts as a functional nAChR antagonist by attenuating nicotine cue-induced craving and, if a smoking lapse occurs during a quit attempt, by blocking nicotine's reinforcing effects and conditioning to novel drug-related stimuli [134–136]. In support of this latter mechanism, VAR has been shown to be effective in reducing smoking lapse behavior in the laboratory [137] and disrupting the transition from smoking lapse to relapse in a smoking cessation trial [138]. Additional mechanisms of action may relate to improvements in working memory [139], attention [140] and inhibitory control [67]. While VAR is the most successful currently available treatment for tobacco use, abstinence rates with patients taking this medication are about 43% at 12 weeks and 25% at one-year follow-up [141]. Thus, even among general smokers, the majority of persons taking VAR are not successful in quitting smoking long-term.

A recent line of research has yielded results in support of VAR as a potential treatment for AUD. It is currently unclear which nAChR receptor type is responsible for alcohol's pharmacological and behavioral effects [76,78,79,142,143], but most evidence does not support the involvement of the  $\alpha 4\beta 2$  nAChR despite this subtype being responsible for much of nicotine's acute and chronic effects and VAR's smoking treatment efficacy [144–148]. However, neurobiological evidence suggests that a nAChR containing the  $\alpha 4$  subunit is necessary and sufficient for VAR's anti-alcohol effects, potentially implicating the relatively



understudied striatal  $\alpha 4\alpha 6\beta 2\beta 3$  nAChR in both alcohol's acute effects and as a novel treatment target for AUD [78,142,149].

Despite the uncertainty about the precise molecular mechanism of action, VAR is thought to produce similar neurobiological and behavioral changes as is observed with nicotine: the nAChR partial agonist effects stimulate VTA dopamine neurons to reduce basal craving and negative mood, while the functional receptor antagonist effects block alcohol reward or alcohol cue-induced craving. In support, VAR has been shown to reduce alcohol self-administration [150], self-reported alcohol craving [151–154], and alcohol and cigarette consumption among general smokers, heavy drinking smokers, and persons with AUD [151–153,155]. Interestingly, one study found that varenicline increased dysphoria and tended to reduce alcohol liking ratings following a controlled alcohol administration in the laboratory, suggesting that varenicline may potentiate the aversive effects of alcohol [156]. Additionally, VAR may improve alcohol's impairment in attention [156] and reduce expectancy for alcohol's positive effects [157]. However, not all studies have found that VAR reduces alcohol consumption or self-administration [154,157,158]. Of note, there is also interest in studying other medications for AUD because of their effects on nAChRs. Mecamylamine, a general nAChR antagonist, blocks the rewarding effects of alcohol in rodents [160] and humans [161], but the results from the first clinical trial testing its effects on alcohol consumption have not been reported (NCT00342563).

Together, these findings suggest that varenicline is an effective treatment for TUD and may have therapeutic effects on alcohol use as well. Therefore, VAR may be a particularly promising pharmacotherapy for heavy drinking smokers, as VAR's ability to blunt alcohol's positively reinforcing effects, potentiate alcohol's aversive effects, and attenuate basal alcohol craving may produce an overall reduction in alcohol consumption. Such beneficial changes in alcohol consumption and cue reactivity may promote smoking abstinence in heavy drinking smokers [159], potentially by reducing the incidence of alcohol-induced smoking lapses. However, the Food and Drug Administration has issued a warning that VAR may affect the manner in which individuals respond to alcohol, including increased intoxication and a rare risk for seizures, and recommends that patients taking VAR decrease alcohol consumption. As this warning was released in 2015, it is presently unclear how this will affect patient and provider receptivity to VAR as a treatment in heavy-drinking smokers, and this potential issue should be closely monitored going forward.

**3.3.2 Naltrexone**—Naltrexone hydrochloride is a competitive opioid receptor antagonist with highest affinity for  $\mu$ -opioid receptors and, accordingly, has been posited to block the hedonically rewarding effects of alcohol and nicotine [63,83,87]. Naltrexone is approved for the treatment of alcohol and opioid use disorders. In alcoholism treatment, its primary efficacy is in reducing relapse to heavy drinking [162] by preventing the transition from a lapse into a full-blown relapse [163,164]. A number of additional studies have found that NTX may also have moderate efficacy in increasing time to first relapse [163,165,166], reducing relapse rates [167,168], reducing the number of drinking days [167], and the number of drinks per drinking episode [166,169].

As the endogenous opioid system also contributes to the behavioral effects of nicotine, NTX has been examined as a smoking cessation aid but results have been mixed [170–174]. The 50 or 100 mg doses of NTX show better treatment outcomes than the 25 mg dose [171–174], which may be attributed to the relatively higher proportion of opioid receptor blockade [175]. The largest trial to date examining 50 mg NTX for smoking cessation recently reported that NTX (plus nicotine patch) improved quit rates over 12 weeks of treatment and lessened the amount of weight gain [171], with the latter finding extending in women through one year after the quit date [176]. As recently shown with VAR [177], these results suggest that smoking outcomes are better for NTX when used in conjunction with nicotine patch to alleviate tobacco withdrawal [171,173,178].

Although current evidence does not support NTX as an effective stand-alone treatment for smoking cessation [179], it is possible that NTX may be a useful adjunct in smoking cessation for heavy drinking smokers. In this subgroup, naltrexone has been shown to reduce alcohol- and cigarette-induced smoking urge, the stimulatory effects of cigarettes, and smoking behavior [180–182]. A re-analysis of The COMBINE Study found that naltrexone was more effective for the treatment of AUD among alcoholics who were also daily smokers than in non-smokers [13]. Furthermore, secondary analyses of three smoking cessation trials with NTX have indicated that heavy drinking smokers were preferentially responsive to NTX, with NTX producing a two-fold higher smoking quit rate in this group compared with placebo [183] while also reducing alcohol consumption [183–185]. Naltrexone's effect on heavy drinking smokers' quit rates was mediated by its effect on reducing smoking urge but not by its reduction in drinking [183], which may suggest independent mechanisms of action for NTX on reducing smoking and drinking in heavy drinking smokers, but further studies are needed to elucidate this possibility.

**3.3.3 Combined varenicline and naltrexone therapy**—It has become increasingly apparent that alcohol and tobacco co-use is a complex biobehavioral problem that requires novel and multifocal treatment approaches. The existing monotherapies for TUD and AUD have shown moderate efficacies at best [141,162]. Therefore, a combination of pharmacotherapies may be more effective at addressing the complex nature of heavy drinking smokers. The selection of treatment combinations requires careful evaluation and ideally consists of two pharmacotherapies with compatible and synergistic behavioral and pharmacological mechanisms of action [186]. The combination of NTX and VAR represent one such potential combination.

A recent human laboratory study has shown that short-term treatment with the combination of VAR and low dose NTX (25 mg) was superior to both monotherapies and placebo in reducing alcohol-induced cigarette craving and better than placebo at attenuating smoking intensity [187] and subsequent craving while smoking the first cigarette of the day [187–189]. These results are consistent with the notion that VAR reduces cigarette craving and attenuates the positive reinforcing effects of smoking through the blockade of  $\alpha 4\beta 2$  nAChRs [75,127,128,135]. Additionally, the combination of VAR + NTX was superior to placebo, and at times monotherapies, in attenuating alcohol and cigarette “high” during the experiment, as well as reducing drinks and cigarettes per drinking day during the 9-day medication titration period before the experimental session. Finally, a subset of participants

also completed a neuroimaging session, which found that the combination of VAR + NTX was associated with reduced activation of the anterior cingulate cortex in response to cigarette cues compared with placebo and NTX [189]. While these laboratory studies suggest that the combination of VAR + NTX may be an effective smoking cessation strategy to improve quit rates and reduce alcohol use in heavy drinking smokers, clinical studies of this combination are needed and are currently underway in order to determine whether combining VAR + NTX yields better clinical outcomes than VAR monotherapy.

## 4 Conclusions

This manuscript sought to review the evidence for the behavioral and molecular mechanisms subserving the co-use of tobacco and alcohol and the treatment implications of these mechanisms. Specifically, we focused on heavy drinking smokers, as they are a sizeable subgroup of daily smokers for whom alcohol use may pose a unique obstacle to successful smoking cessation [11,12]. Evidence from experimental studies in humans has suggested that alcohol and nicotine act synergistically to reinforce co-use behavior by inducing craving for the other substance, potentiating the rewarding effects of each drug and blunting alcohol's sedating and impairing effects. This co-reinforcement and cue-cross-reactivity contributes to increased cigarette and alcohol use within an episode and overtime likely contributes to the development of comorbid AUD and TUD, as often observed in heavy drinking smokers. As we reviewed the molecular underpinning of the co-use of nicotine and alcohol, we argued that the behavioral effects of co-administration are, in part, due to shared pharmacological targets in the acetylcholine and endogenous opioid systems. In translating these findings to pharmacological treatments, we contend that nAChRs and  $\mu$ -opioid receptors may be promising molecular targets for the development of treatments for heavy drinking smokers.

Based on the recognition of nAChRs and  $\mu$ -opioid receptors as plausible targets for pharmacological treatments of heavy drinking smokers, the evidence for NTX, VAR, and their combination was reviewed suggesting that there may be benefits for each medication alone and also potentially for the combination of these medications as dual therapy. While initial controlled experimental and neuroimaging studies have supported the combination of VAR + NTX over placebo and monotherapy, until additional research is completed these findings are not yet applicable to clinical populations. Finally, more studies are needed to determine whether behavioral and psychosocial interventions can effectively reduce alcohol and tobacco co-use, either as stand-alone treatment or in conjunction with pharmacotherapy. Development of optimal strategies may be hampered by reduced enthusiasm at granting agencies to conduct research on established or repurposed medications for alcohol addiction, i.e., NIAAA's NOT-AA-14-009, as this also includes clinical studies of such treatments in heavy-drinking smokers. Thus, this particularly high-risk co-using subgroup could be further marginalized in standard treatment programs or physician's offices as there are no guidelines and evidence-based treatments for providers to utilize. Heavy drinking smokers then will continue to incur health disparities compared with non- and light-drinking smokers in terms of cancer and other early mortality risks.

In conclusion, there is ample evidence from a host of experimental, molecular, and clinical studies that heavy drinking smokers comprise a unique group of substance users. Elucidating the behavioral and underlying molecular mechanisms subserving alcohol and tobacco co-use has the potential to inform personalized treatments for this sub-group of smokers. This review demonstrated that knowledge deriving from epidemiological data on co-use, behavioral findings from laboratory and in-vivo studies, basic bench science, and clinical trials can be better understood and integrated to inform treatment development based on patients unique vulnerabilities. While much work remains to be done before more effective guidelines of care can be offered to heavy drinking smokers, this approach holds promise as a road map for implementing precision medicine efforts applying to both AUD and TUD.

## Acknowledgments

Lara Ray has received medication from Pfizer and Medicinova and has consulted for GSK.

## References

Papers of particular interest, published recently, have been highlighted as:

\* Of importance

\*\* Of major importance

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA*. 2004; 291:1238–1245. [PubMed: 15010446]
2. Organization WH. World Health Organization; 2010. World Health Statistics 2010.
3. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. *Nat. Neurosci*. 2005; 8:1465–1470. [PubMed: 16251989]
4. Kalman D, Morissette SB, George TP. Co-Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders. *Am. J. Addict*. 2005; 14:106–123. [PubMed: 16019961]
5. Harrison ELR, Desai RA, McKee SA. Nondaily Smoking and Alcohol Use, Hazardous Drinking, and Alcohol Diagnoses Among Young Adults: Findings From the NESARC. *Alcohol. Clin. Exp. Res*. 2008; 32:2081–2087. [PubMed: 18828805]
6. Negri E, Vecchia CL, Franceschi S, Tavani A. Attributable risk for oral cancer in northern Italy. *Cancer Epidemiol. Biomarkers Prev*. 1993; 2:189–193. [PubMed: 8318870]
7. Durazzo TC, Gazdzinski S, Meyerhoff DJ. The neurobiological and neurocognitive consequences of chronic cigarette smoking in alcohol use disorders. *Alcohol Alcohol*. 2007; 42:174–185. [PubMed: 17526627]
8. Pelucchi C, Gallus S, Garavello W, Bosetti C, La Vecchia C. Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. *Eur. J. Cancer Prev*. 2008; 17:340–344. [PubMed: 18562959]
9. Prabhu A, Obi KO, Rubenstein JH. The Synergistic Effects of Alcohol and Tobacco Consumption on the Risk of Esophageal Squamous Cell Carcinoma: A Meta-Analysis. *Am. J. Gastroenterol*. 2014; 109:822–827. [PubMed: 24751582]
10. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment: Role of tobacco use in a community-based cohort. *JAMA*. 1996; 275:1097–1103. [PubMed: 8601929]
11. Collins FS, Varmus H. A new initiative on precision medicine. *N. Engl. J. Med*. 2015; 372:793–795. [PubMed: 25635347]
12. Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. *Alcohol. Clin. Exp. Res*. 2015; 39:579–584. [PubMed: 25833016]
- 13.

- Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O'Malley SS. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. *Biol. Psychiatry*. 2012; 72:832–888. [PubMed: 22541040] A reanalysis of the COMBINE study indicated that individuals with an AUD who were also smokers may have better alcohol treatment outcomes than nonsmokers.
14. Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. *J. Stud. Alcohol*. 2004; 65:681–691. [PubMed: 15700504]
  15. Piasecki TM, McCarthy DE, Fiore MC, Baker TB. Alcohol consumption, smoking urge, and the reinforcing effects of cigarettes: An ecological study. *Psychol. Addict. Behav*. 2008; 22:230–239. [PubMed: 18540720]
  16. Piasecki TM, Jahng S, Wood PK, Robertson BM, Epler AJ, Cronk NJ, et al. The subjective effects of alcohol–tobacco co-use: An ecological momentary assessment investigation. *J. Abnorm. Psychol*. 2011; 120:557–571. [PubMed: 21443289]
  17. SAMHSA. Mental Health Services Administration (SAMHSA). Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockv. MD: Subst. Abuse Ment. Health Serv. Adm; 2014. NSDUH Series H-48, HHS Publication No.(SMA) 14-4863.
  18. Dawson DA. Drinking as a risk factor for sustained smoking. *Drug Alcohol Depend*. 2000; 59:235–249. [PubMed: 10812284]
  19. Ockene JK, Adams A. Screening and intervention for smoking and alcohol use in primary care settings: similarities, differences, gaps, and challenges. *Alcohol Tob. Basic Sci. Clin. Pract. Natl. Inst. Health*. 1995:281–294.
  20. Shiffman S, Tindle H, Li X, Scholl S, Dunbar M, Mitchell-Miland C. Characteristics and smoking patterns of intermittent smokers. *Exp. Clin. Psychopharmacol*. 2012; 20:264–277. [PubMed: 22390208]
  21. McKee SA, Weinberger AH. How Can We Use Our Knowledge of Alcohol-Tobacco Interactions to Reduce Alcohol Use? *Annu. Rev. Clin. Psychol*. 2013; 9:649–674. [PubMed: 23157448]
  22. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. *Drug Alcohol Depend*. 2004; 74:223–234. [PubMed: 15194200]
  23. Room R. Smoking and drinking as complementary behaviours. *Biomed. Pharmacother*. 2004; 58:111–115. [PubMed: 14992792]
  24. Falk DE, Yi H, Hiller-Sturmhofel S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders. *Alcohol Res Health*. 2006; 29:162–171. [PubMed: 17373404]
  25. Niaura RS, Rohsenow DJ, Binkoff JA, Monti PM, Pedraza M, Abrams DB. Relevance of cue reactivity to understanding alcohol and smoking relapse. *J. Abnorm. Psychol*. 1988; 97:133–152. [PubMed: 3290304]
  26. Tiffany, ST. Potential functions of classical conditioning in drug addiction. In: Drummond, DC.; Tiffany, ST.; Glautier, S.; Remington, B., editors. *Addict. Behav. Cue Expo. Theory Pract*. Oxford, England: John Wiley & Sons; 1995. p. 47-71.
  27. Perkins KA. Combined effects of nicotine and alcohol on subjective, behavioral and physiological responses in humans. *Addict. Biol*. 1997; 2:255–268. [PubMed: 26735782]
  28. Burton SM, Tiffany ST. The effect of alcohol consumption on craving to smoke. *Addiction*. 1997; 92:15–26. [PubMed: 9060194]
  29. Sayette MA, Martin CS, Wertz JM, Perrott MA, Peters AR. The effects of alcohol on cigarette craving in heavy smokers and tobacco chippers. *Psychol. Addict. Behav*. 2005; 19:263–270. [PubMed: 16187804]
  30. King AC, Epstein AM. Alcohol dose–dependent increases in smoking urge in light smokers. *Alcohol. Clin. Exp. Res*. 2005; 29:547–552. [PubMed: 15834219]
  31. Kouri EM, McCarthy EM, Faust AH, Lukas SE. Pretreatment with transdermal nicotine enhances some of ethanol's acute effects in men. *Drug Alcohol Depend*. 2004; 75:55–65. [PubMed: 15225889]

32. King A, McNamara P, Conrad M, Cao D. Alcohol-induced increases in smoking behavior for nicotinized and denicotinized cigarettes in men and women. *Psychopharmacology (Berl.)*. 2009; 207:107–117. [PubMed: 19756530]
33. Epstein AM, Sher TG, Young MA, King AC. Tobacco chippers show robust increases in smoking urge after alcohol consumption. *Psychopharmacology (Berl.)*. 2006; 190:321–329. [PubMed: 16804691]
34. King AC, de Wit H, McNamara PJ, Cao D. Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. *Arch. Gen. Psychiatry*. 2011; 68:389–399. [PubMed: 21464363]
35. Roche DJO, Palmeri MD, King AC. Acute alcohol response phenotype in heavy social drinkers is robust and reproducible. *Alcohol. Clin. Exp. Res.* 2014; 38:844–852. [PubMed: 24117681]
36. Cooney NL, Litt MD, Cooney JL, Pilkey DT, Steinburg HR, Oncken CA. Alcohol and tobacco cessation in alcohol-dependent smokers: Analysis of real-time reports. *Psychol. Addict. Behav.* 2007; 21:277–286. [PubMed: 17874878]
37. Oliver JA, Blank MD, Van Rensburg KJ, MacQueen DA, Brandon TH, Drobos DJ. Nicotine interactions with low-dose alcohol: Pharmacological influences on smoking and drinking motivation. *J. Abnorm. Psychol.* 2013; 122:1154–1165. [PubMed: 24364618]
38. McKee SA, O'Malley SS, Shi J, Mase T, Krishnan-Sarin S. Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. *Psychopharmacology (Berl.)*. 2008; 196:189–200. [PubMed: 17912500]
39. McKee SA, Krishnan-Sarin S, Shi J, Mase T, O'Malley SS. Modeling the effect of alcohol on smoking lapse behavior. *Psychopharmacology (Berl.)*. 2006; 189:201–210. [PubMed: 17013640]
40. Kahler CW, Metrik J, Spillane NS, Day A, Leventhal AM, McKee SA, et al. Acute effects of low and high dose alcohol on smoking lapse behavior in a laboratory analogue task. *Psychopharmacology (Berl.)*. 2014; 231:4649–4657. [PubMed: 24858377]
41. Perkins KA, Fonte C, Grobe JE. Sex differences in the acute effects of cigarette smoking on the reinforcing value of alcohol. *Behav. Pharmacol.* 2000; 11:63–70. [PubMed: 10821210]
42. Barrett SP, Tichauer M, Leyton M, Pihl RO. Nicotine increases alcohol self-administration in non-dependent male smokers. *Drug Alcohol Depend.* 2006; 81:197–204. [PubMed: 16054779]
43. Acheson A, Mahler SV, Chi H, Wit H de. Differential effects of nicotine on alcohol consumption in men and women. *Psychopharmacology (Berl.)*. 2006; 186:54–63. [PubMed: 16565827]
44. Bujarski S, Hutchison KE, Roche DJO, Ray LA. Factor structure of subjective responses to alcohol in light and heavy drinkers. *Alcohol. Clin. Exp. Res.* 2015; 39:1193–1202. [PubMed: 26010049]
45. Wit, H de; Doty, P. Preference for ethanol and diazepam in light and moderate social drinkers: a within-subjects study. *Psychopharmacology (Berl.)*. 1994; 115:529–538. [PubMed: 7871098]
46. Corbin WR, Gearhardt A, Fromme K. Stimulant alcohol effects prime within session drinking behavior. *Psychopharmacology (Berl.)*. 2007; 197:327–337. [PubMed: 18084744]
47. De Wit H, Pierri J, Johanson CE. Reinforcing and subjective effects of diazepam in nondrug-abusing volunteers. *Pharmacol. Biochem. Behav.* 1989; 33:205–213. [PubMed: 2780778]
48. Chutuape MAD, De Wit H. Relationship between subjective effects and drug preferences: ethanol and diazepam. *Drug Alcohol Depend.* 1994; 34:243–251. [PubMed: 8033763]
49. Perkins KA, Sexton JE, DiMarco A, Grobe JE, Scierka A, Stiller RL. Subjective and cardiovascular responses to nicotine combined with alcohol in male and female smokers. *Psychopharmacology (Berl.)*. 1995; 119:205–212. [PubMed: 7659768]
50. Perkins KA, Grobe JE, Fonte C, Goettler J, Caggiola AR, Reynolds WA, et al. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. *J. Pharmacol. Exp. Ther.* 1994; 270:628–638. [PubMed: 8071855]
51. Glautier S, Clements K, White JaW, Taylor C, Stolerman IP. Alcohol and the reward value of cigarette smoking. *Behav. Pharmacol.* 1996; 7:144–154. [PubMed: 11224406]
52. Rose JE, Brauer LH, Behm FM, Cramblett M, Calkins K, Lawhon D. Potentiation of nicotine reward by alcohol. *Alcohol. Clin. Exp. Res.* 2002; 26:1930–1931. [PubMed: 12500124]
53. Rose J, Brauer L, Behm F, Cramblett M, Calkins K, Lawhon D. Psychopharmacological interactions between nicotine and ethanol. *Nicotine Tob. Res.* 2004; 6:133–144. [PubMed: 14982697]

54. Madden PA, Heath AC, Starmer GA, Whitfield JB, Martin NG. Alcohol sensitivity and smoking history in men and women. *Alcohol. Clin. Exp. Res.* 1995; 19:1111–1120. [PubMed: 8561278]
55. Ralevski E, Perry EB, D'Souza DC, Bufis V, Elander J, Limoncelli D, et al. Preliminary findings on the interactive effects of iv ethanol and iv nicotine on human behavior and cognition: a laboratory study. *Nicotine Tob. Res.* 2012; 14:596–606. [PubMed: 22180582]
56. Michel C, Bättig K. Separate and combined psychophysiological effects of cigarette smoking and alcohol consumption. *Psychopharmacology (Berl.)*. 1989; 97:65–73. [PubMed: 2496429]
57. Kerr JS, Sherwood N, Hindmarch I. Separate and combined effects of the social drugs on psychomotor performance. *Psychopharmacology (Berl.)*. 1991; 104:113–119. [PubMed: 1881996]
58. Harrison ELR, Hinson RE, McKee SA. Experimenting and daily smokers: Episodic patterns of alcohol and cigarette use. *Addict. Behav.* 2009; 34:484–486. [PubMed: 19176271]
59. Harrison ELR, McKee SA. Non-daily smoking predicts hazardous drinking and alcohol use disorders in young adults in a longitudinal U.S. sample. *Drug Alcohol Depend.* 2011; 118:78–82. [PubMed: 21441000]
60. Funk D, Marinelli PW, Le AD. Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors. *Alcohol Res. Health.* 2006; 29:186. [PubMed: 17373407]
61. King A, McNamara P, Angstadt M, Phan KL. Neural substrates of alcohol-induced smoking urge in heavy drinking nondaily smokers. *Neuropsychopharmacology.* 2009; 35:692–701. [PubMed: 19907419]
62. Drews E, Zimmer A. Modulation of alcohol and nicotine responses through the endogenous opioid system. *Prog. Neurobiol.* 2010; 90:1–15. [PubMed: 19800387]
63. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. *Physiol. Rev.* 2009; 89:649–705. [PubMed: 19342616]
64. Widdowson PS, Holman RB. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. *J. Neurochem.* 1992; 59:157–163. [PubMed: 1613496]
65. Trigo JM, Martín-García E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction. *Drug Alcohol Depend.* 2010; 108:183–194. [PubMed: 19945803]
66. Hendrickson LM, Guildford MJ, Tapper AR. Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. *Front. Psychiatry.* 2013; 4
67. Austin AJ, Duka T, Rusted J, Jackson A. Effect of varenicline on aspects of inhibitory control in smokers. *Psychopharmacology (Berl.)*. 2014; 231:3771–3785. [PubMed: 24652107]
68. Patterson F, Jepson C, Strasser AA, Loughhead J, Perkins KA, Gur RC, et al. Varenicline improves mood and cognition during smoking abstinence. *Biol. Psychiatry.* 2009; 65:144–149. [PubMed: 18842256]
69. Boettiger CA, Kelley EA, Mitchell JM, D'Esposito M, Fields HL. Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. *Pharmacol. Biochem. Behav.* 2009; 93:291–299. [PubMed: 19258022]
70. Grant JE, Odlaug BL, Schreiber LRN, Kim SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. *J. Clin. Psychopharmacol.* 2014; 34:134–138. [PubMed: 24145220]
71. Zhou F-M, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. *Nat. Neurosci.* 2001; 4:1224–1229. [PubMed: 11713470]
72. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. *Neuron.* 2012; 76:470–485. [PubMed: 23141060]
73. Doyon WM, Thomas AM, Ostroumov A, Dong Y, Dani JA. Potential substrates for nicotine and alcohol interactions: A focus on the mesocorticolimbic dopamine system. *Biochem. Pharmacol.* 2013; 86:1181–1193. [PubMed: 23876345]
74. Yang K, Jin G, Wu J. Mysterious  $\alpha 6$ -containing nAChRs: function, pharmacology, and pathophysiology. *Acta Pharmacol. Sin.* 2009; 30:740–751. [PubMed: 19498417]
75. De Biasi M, Dani JA. Reward, Addiction, Withdrawal to Nicotine. *Annu. Rev. Neurosci.* 2011; 34:105–130. [PubMed: 21438686]

76. Larsson A, Jerlhag E, Svensson L, Söderpalm B, Engel JA. Is an  $\alpha$ -conotoxin MII-sensitive mechanism involved in the neurochemical, stimulatory, and rewarding effects of ethanol? *Alcohol*. 2004; 34:239–250. [PubMed: 15902919]
77. Jerlhag E. Role of the subunit composition of central nicotinic acetylcholine receptors for the stimulatory and dopamine-enhancing effects of ethanol. *Alcohol*. 2006; 41:486–493. [PubMed: 16799162]
78. Liu L, Hendrickson LM, Guildford MJ, Zhao-Shea R, Gardner PD, Tapper AR. Nicotinic acetylcholine receptors containing the  $\alpha 4$  subunit modulate alcohol reward. *Biol. Psychiatry*. 2013; 73:738–746. [PubMed: 23141806]
79. Powers MS, Broderick HJ, Drenan RM, Chester JA. Nicotinic acetylcholine receptors containing  $\alpha 6$  subunits contribute to alcohol reward-related behaviours:  $\alpha 6$ -Containing nAChRs contribute to alcohol reward. *Genes Brain Behav*. 2013; 12:543–553. [PubMed: 23594044]
80. Hauser SR, Getachew B, Oster SM, Dhaher R, Ding Z-M, Bell RL, et al. Nicotine modulates alcohol-seeking and relapse by alcohol-preferring (P) rats in a time-dependent manner. *Alcohol. Clin. Exp. Res*. 2012; 36:43–54. [PubMed: 21689122]
81. Söderpalm, B.; Ericson, M. Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points. In: Sommer, WH.; Spanagel, R., editors. *Behav. Neurobiol. Alcohol Addict*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 127-161.
82. Clark A, Little H. Interactions between low concentrations of ethanol and nicotine on firing rate of ventral tegmental dopamine neurones. *Drug Alcohol Depend*. 2004; 75:199–206. [PubMed: 15276226]
83. Berrendero F, Robledo P, Trigo JM, Martín-García E, Maldonado R. Neurobiological mechanisms involved in nicotine dependence and reward: Participation of the endogenous opioid system. *Neurosci. Biobehav. Rev*. 2010; 35:220–231. [PubMed: 20170672]
84. Berridge KC, Robinson TE, Aldridge JW. Dissecting components of reward: “liking”, “wanting”, and learning. *Curr. Opin. Pharmacol*. 2009; 9:65–73. [PubMed: 19162544]
85. Olive MF, Koenig HN, Nannini MA, Hodge CW. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. *J. Neurosci. Off. J. Soc. Neurosci*. 2001; 21:RC184.
86. Nestler EJ. Is there a common molecular pathway for addiction? *Nat. Neurosci*. 2005; 8:1445–1449. [PubMed: 16251986]
87. Herz A. Endogenous opioid systems and alcohol addiction. *Psychopharmacology (Berl.)*. 1997; 129:99–111. [PubMed: 9040115]
88. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. *J. Neurosci*. 1998; 18:10663–10671. [PubMed: 9852601]
89. Hall FS, Sora I, Uhl GR. Ethanol consumption and reward are decreased in  $\mu$ -opiate receptor knockout mice. *Psychopharmacology (Berl.)*. 2001; 154:43–49. [PubMed: 11292005]
90. Marty MA, Erwin VG, Cornell K, Zgombick JM. Effects of nicotine on  $\beta$ -endorphin,  $\alpha$ MSH, and ACTH secretion by isolated perfused mouse brains and pituitary glands, in Vitro. *Pharmacol. Biochem. Behav*. 1985; 22:317–325. [PubMed: 2984705]
91. Dhatt RK, Gudehithlu KP, Wemlinger TA, Tejwani GA, Neff NH, Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. *J. Neurochem*. 1995; 64:1878–1883. [PubMed: 7891117]
92. Gudehithlu KP, Duchemin A-M, Tejwani GA, Neff NH, Hadjiconstantinou M. Nicotine-induced changes of brain  $\beta$ -endorphin. *Neuropeptides*. 2012; 46:125–131. [PubMed: 22483037]
93. Tanda G, Di Chiara G. A dopamine- $\mu 1$  opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. *Eur. J. Neurosci*. 1998; 10:1179–1187. [PubMed: 9753186]
94. Maisonneuve IM, Glick SD. (+/-)Cyclazocine blocks the dopamine response to nicotine. *Neuroreport*. 1999; 10:693–696. [PubMed: 10208532]
95. Rezayof A, Nazari-Serenjeh F, Zarrindast M-R, Sepehri H, Delphi L. Morphine-induced place preference: Involvement of cholinergic receptors of the ventral tegmental area. *Eur. J. Pharmacol*. 2007; 562:92–102. [PubMed: 17336285]



96. Zarrindast M-R, Faraji N, Rostami P, Sahraei H, Ghoshouni H. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. *Pharmacol. Biochem. Behav.* 2003; 74:363–369. [PubMed: 12479956]
97. Liu X, Palmatier MI, Caggiula AR, Sved AF, Donny EC, Gharib M, et al. Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. *Psychopharmacology (Berl.)*. 2008; 202:589–598. [PubMed: 18807246]
98. Corrigan WA, Coen KM, Adamson KL, Chow BLC, Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and  $\gamma$ -aminobutyric acid receptors in the ventral tegmental area. *Psychopharmacology (Berl.)*. 2000; 149:107–114. [PubMed: 10805604]
99. DeNoble VJ, Mele PC. Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. *Psychopharmacology (Berl.)*. 2005; 184:266–272. [PubMed: 16088413]
100. Wee S, Koob GF. The role of the dynorphin- $\kappa$  opioid system in the reinforcing effects of drugs of abuse. *Psychopharmacology (Berl.)*. 2010; 210:121–135. [PubMed: 20352414]
101. Jackson KJ, McLaughlin JP, Carroll FI, Damaj MI. Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice. *Psychopharmacology (Berl.)*. 2012; 226:763–768. [PubMed: 22526543]
102. Shippenberg TS. The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders? *Neuropsychopharmacology*. 2009; 34:247–247. [PubMed: 19079072]
103. Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. *Tob. Control.* 1997; 6:S57. [PubMed: 9583654]
104. Kahler CW, Spillane NS, Metrik J. Alcohol use and initial smoking lapses among heavy drinkers in smoking cessation treatment. *Nicotine Tob. Res.* 2010 ntq083.
105. Kahler CW, Metrik J, LaChance HR, Ramsey SE, Abrams DB, Monti PM, et al. Addressing heavy drinking in smoking cessation treatment: A randomized clinical trial. *J. Consult. Clin. Psychol.* 2008; 76:852–862. [PubMed: 18837602]
106. Toll BA, Cummings KM, O'Malley SS, Carlin-Menter S, McKee SA, Hyland A, et al. Tobacco Quitlines Need to Assess and Intervene with Callers' Hazardous Drinking. *Alcohol. Clin. Exp. Res.* 2012; 36:1653–1658. [PubMed: 22703028]
107. Brandon TH, Tiffany ST, Obremski KM, Baker TB. Postcessation cigarette use: The process of relapse. *Addict. Behav.* 1990; 15:105–114. [PubMed: 2343783]
108. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation: Who will quit with and without the nicotine patch. *JAMA.* 1994; 271:589–594. [PubMed: 8301790]
109. Garvey AJ, Bliss RE, Hitchcock JL, Heinold JW, Rosner B. Predictors of smoking relapse among self-quitters: A report from the normative aging study. *Addict. Behav.* 1992; 17:367–377. [PubMed: 1502970]
110. Shiffman S, Hickcox M, Paty JA, Gnys M, Kassel JD, Richards TJ. Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. *J. Consult. Clin. Psychol.* 1996; 64:993–1002. [PubMed: 8916628]
111. Shiffman S, Ferguson SG, Gwaltney CJ. Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy. *Psychopharmacology (Berl.)*. 2006; 184:608–618. [PubMed: 16283258]
112. Shiffman S. A cluster-analytic classification of smoking relapse episodes. *Addict. Behav.* 1986; 11:295–307. [PubMed: 3739816]
113. Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. *J. Consult. Clin. Psychol.* 1996; 64:366–379. [PubMed: 8871421]
114. Littleton J, Barron S, Prendergast M, Nixon SJ. Smoking kills (alcoholics)! shouldn't we do something about it? *Alcohol Alcohol.* 2007; 42:167–173. [PubMed: 17526626]

115. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. *Am. J. Prev. Med.* 2008; 35:158–176. [PubMed: 18617085]
116. Leeman RF, Huffman CJ, O'Malley SS. Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review. *Alcohol Alcohol.* 2007; 42:196–206. [PubMed: 17526629]
117. Leeman RF, McKee SA, Toll BA, Krishnan-Sarin S, Cooney JL, Makuch RW, et al. Risk factors for treatment failure in smokers: relationship to alcohol use and to lifetime history of an alcohol use disorder. *Nicotine Tob. Res. Off. J. Soc. Res. Nicotine Tob.* 2008; 10:1793.
118. Toll BA, Martino S, O'Malley SS, Fucito LM, McKee SA, Kahler CW, et al. A randomized trial for hazardous drinking and smoking cessation for callers to a quitline. *J. Consult. Clin. Psychol.* 2015; 83:445–454. [PubMed: 25419583] This study demonstrated that a behavioral intervention via telephone quitline that included both alcohol and tobacco counseling was more effective in producing smoking abstinence in heavy drinking smokers than tobacco-only counseling.
119. Fridberg DJ, Cao D, King AC. Integrating alcohol response feedback in a brief intervention for young adult heavy drinkers who smoke: A pilot study. *Drug Alcohol Depend.* 2015; 155:293–297. [PubMed: 26341847] This study indicated that a behavioral intervention that included personalized feedback on how an individual's subjective response to alcohol may increase future risk for AUD was more effective than standard alcohol brief interventions in reducing drinking and smoking behavior in heavy drinking smokers.
120. Wiers RW, Eberl C, Rinck M, Becker ES, Lindenmeyer J. Retraining automatic action tendencies changes alcoholic patients' approach bias for alcohol and improves treatment outcome. *Psychol. Sci.* 2011; 22:490–497. [PubMed: 21389338]
121. Fiore, M. Diane Publishing. Rockville, MD: 2008. Treating tobacco use and dependence: 2008 update: Clinical practice guideline.
122. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Varenicline Phase 3 Study Group: Efficacy of varenicline, an  $\alpha 4\beta 2$  nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA.* 2006; 296:56–63. [PubMed: 16820547]
123. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Arch. Intern. Med.* 2006; 166:1571–1577. [PubMed: 16908789]
124. Williams KE, Reeves KR, CBB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. *Curr. Med. Res. Opin.* 2007; 23:793–801. [PubMed: 17407636]
125. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. *Ann. Med.* 2012; 44:588–597. [PubMed: 22860882]
126. Mihalak KB. Varenicline is a partial agonist at  $\alpha 4\beta 2$  and a full agonist at  $\alpha 7$  neuronal nicotinic receptors. *Mol. Pharmacol.* 2006; 70:801–805. [PubMed: 16766716]
127. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. Pharmacological profile of the  $\alpha 4\beta 2$  nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. *Neuropharmacology.* 2007; 52:985–994. [PubMed: 17157884]
128. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: An  $\alpha 4\beta 2$  Nicotinic Receptor Partial Agonist for Smoking Cessation. *J. Med. Chem.* 2005; 48:3474–3477. [PubMed: 15887955]
129. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the  $\beta 2$  subunit are involved in the reinforcing properties of nicotine. *Nature.* 1998; 391:173–177. [PubMed: 9428762]

130. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation of  $\alpha 4^*$  receptors: sufficient for reward, tolerance, and sensitization. *Science*. 2004; 306:1029–1032. [PubMed: 15528443]
131. Biala G, Staniak N, Budzynska B. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. *Naunyn. Schmiedebergs Arch. Pharmacol.* 2010; 381:361–370. [PubMed: 20217050]
132. Sanjakdar SS, Maldoon PP, Marks MJ, Brunzell DH, Maskos U, McIntosh JM, et al. Differential roles of  $\alpha 6\beta 2^*$  and  $\alpha 4\beta 2^*$  neuronal nicotinic receptors in nicotine-and cocaine-conditioned reward in mice. *Neuropsychopharmacology*. 2015; 40:350–360. [PubMed: 25035086]
133. Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA. Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. *J. Psychopharmacol. (Oxf.)*. 2012; 26:1383–1390.
134. Ray LA, Lunny K, Bujarski S, Moallem N, Krull JL, Miotto K. The effects of varenicline on stress-induced and cue-induced craving for cigarettes. *Drug Alcohol Depend.* 2013; 131:136–142. [PubMed: 23298651]
135. Brandon TH, Drobos DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim RC, et al. Varenicline effects on craving, cue reactivity, and smoking reward. *Psychopharmacology (Berl.)*. 2011; 218:391–403. [PubMed: 21559801]
136. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, et al. Effects of varenicline on smoking cue-triggered neural and craving responses. *Arch. Gen. Psychiatry*. 2011; 68:516. [PubMed: 21199958]
137. McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and validating a human laboratory model to screen medications for smoking cessation. *Nicotine Tob. Res. Off. J. Soc. Res. Nicotine Tob.* 2012; 14:1362–1371.
138. McClure EA, Vandrey RG, Johnson MW, Stitzer ML. Effects of varenicline on abstinence and smoking reward following a programmed lapse. *Nicotine Tob. Res.* 2013; 15:139–148. [PubMed: 22573730]
139. Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S, et al. Working memory deficits predict short-term smoking resumption following brief abstinence. *Drug Alcohol Depend.* 2010; 106:61–64. [PubMed: 19733449]
140. Rhodes JD, Hawk LW, Ashare RL, Schlienz NJ, Mahoney MC. The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. *Psychopharmacology (Berl.)*. 2012; 223:131–138. [PubMed: 22526531]
141. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst. Rev.* 2012; 4 CD006103.
142. Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR. Activation of  $4^*$  nAChRs is Necessary and Sufficient for Varenicline-Induced Reduction of Alcohol Consumption. *J. Neurosci.* 2010; 30:10169–10176. [PubMed: 20668200]
143. Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, et al. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area  $6 2^*$  receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. *J. Neurosci.* 2010; 30:5311–5325. [PubMed: 20392953]
144. Lê AD, Corrigan WA, Harding JW, Juzysch W, Li TK. Involvement of nicotinic receptors in alcohol self-administration. *Alcohol. Clin. Exp. Res.* 2000; 24:155–163. [PubMed: 10698366]
145. Larsson A, Svensson L, Söderpalm B, Engel JA. Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. *Alcohol*. 2002; 28:157–167. [PubMed: 12551757]
146. Ericson M, Molander A, Löf E, Engel JA, Söderpalm B. Ethanol elevates accumbal dopamine levels via indirect activation of ventral tegmental nicotinic acetylcholine receptors. *Eur. J. Pharmacol.* 2003; 467:85–93. [PubMed: 12706460]
147. Löf E, Olausson P, deBejczy A, Stomberg R, McIntosh JM, Taylor JR, et al. Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. *Psychopharmacology (Berl.)*. 2007; 195:333–343. [PubMed: 17703283]

148. Chatterjee S, Steensland P, Simms JA, Holgate J, Coe JW, Hurst RS, et al. Partial agonists of the  $\alpha 3\beta 4^*$  neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. *Neuropsychopharmacology*. 2011; 36:603–615. [PubMed: 21048701]
149. Hendrickson LM, Gardner P, Tapper AR. Nicotinic acetylcholine receptors containing the  $\alpha 4$  subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption. *Channels*. 2011; 5:124–127. [PubMed: 21239887]
150. McKee SA, Harrison ELR, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. *Biol. Psychiatry*. 2009; 66:185–190. [PubMed: 19249750]
151. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. *Psychopharmacology (Berl.)*. 2011; 215:655–663. [PubMed: 21221531]
152. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. *Psychopharmacology (Berl.)*. 2012; 223:299–306. [PubMed: 22547331]
153. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. *J. Addict. Med.* 2013; 7:277–286. [PubMed: 23728065] This study was one of the first clinical trials designed to examine varenicline as a treatment for AUD, finding that varenicline (vs. placebo) was effective in reducing heavy drinking days and alcohol craving.
154. Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. *Psychopharmacology (Berl.)*. 2014; 231:3799–3807. [PubMed: 24647921]
155. McKee SA, Young-Wolff KC, Harrison ELR, Cummings KM, Borland R, Kahler CW, et al. Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey. *Alcohol. Clin. Exp. Res.* 2013; 37:804–810. [PubMed: 23240586] This longitudinal, epidemiological study in almost five thousand smokers indicated that patients taking varenicline for smoking cessation were more likely to reduce drinking than patients taking nicotine replacement therapy or no medication.
156. Childs E, Roche DJO, King AC, de Wit H. Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements: varenicline effects on alcohol responses. *Alcohol. Clin. Exp. Res.* 2012; 36:906–914. [PubMed: 22339626]
157. Vatsalya V, Gowin JL, Schwandt ML, Momenan R, Coe MA, Cooke ME, et al. Effects of varenicline on neural correlates of alcohol salience in heavy drinkers. *Int. J. Neuropsychopharmacol. Off. Sci. J. Coll. Int. Neuropsychopharmacol. CINP*. 2015
158. Plebani JG, Lynch KG, Rennert L, Pettinati HM, O'Brien CP, Kampman KM. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. *Drug Alcohol Depend.* 2013; 133:754–758. [PubMed: 23916324]
159. Falk DE, Castle I-JP, Ryan M, Fertig J, Litten RZ. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. *J. Addict. Med.* 2015; 9:296–303. [PubMed: 26083958] In a secondary analysis of 153, this study showed that patients who reduced their cigarette smoking behavior had better alcohol treatment outcomes with varenicline than those who did not decrease their number of cigarettes per day.
160. Bhutada P, Mundhada Y, Ghodki Y, Dixit P, Umathe S, Jain K. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of exposure to stress and modulation by mecamylamine. *J. Psychopharmacol. (Oxf.)*. 2012; 26:315–323.
161. Chi H, de Wit H. Mecamylamine Attenuates the subjective stimulant-like effects of alcohol in social drinkers. *Alcohol. Clin. Exp. Res.* 2003; 27:780–786. [PubMed: 12766622]

162. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. *Cochrane Database Syst. Rev.* 2010 CD001867.
163. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. *Am. J. Psychiatry.* 1999; 156:1758–1764. [PubMed: 10553740]
164. Ray LA, Krull JL, Leggio L. The effects of naltrexone among alcohol non-abstainers: results from the COMBINE study. *Front. Psychiatry.* 2010; 1
165. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. *Arch. Gen. Psychiatry.* 2003; 60:92–99. [PubMed: 12511176]
166. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramírez M, et al. A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. *Alcohol. Clin. Exp. Res.* 2002; 26:1381–1387. [PubMed: 12351933]
167. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. *Arch. Gen. Psychiatry.* 1992; 49:876–880. [PubMed: 1345133]
168. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. *Med. J. Aust.* 2002; 176:530–534. [PubMed: 12064984]
169. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. *Alcohol Alcohol.* 2000; 35:587–593. [PubMed: 11093966]
170. King A, de Wit H, Riley R, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. *Nicotine Tob. Res.* 2006; 8:671–682. [PubMed: 17008194]
171. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, de Wit H, et al. Effects of Naltrexone on Smoking Cessation Outcomes and Weight Gain in Nicotine-Dependent Men and Women: *J. Clin. Psychopharmacol.* 2012; 32:630–636. [PubMed: 22926596]
172. Covey LS, MD AHG, Fay Stetner MAM. Naltrexone effects on short-term and long-term smoking cessation. *J. Addict. Dis.* 1999; 18:31–40. [PubMed: 10234561]
173. O'Malley SS, Cooney JL, Krishnan-Sarin S, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. *Arch. Intern. Med.* 2006; 166:667–674. [PubMed: 16567607]
174. Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, et al. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. *Drug Alcohol Depend.* 2010; 111:200–206. [PubMed: 20542391]
175. Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, et al. Differences in  $\delta$ - and  $\mu$ -opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. *Neuropsychopharmacology.* 2008; 33:653–665. [PubMed: 17487229]
176. King AC, Cao D, Zhang L, O'Malley SS. Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. *Biol. Psychiatry.* 2013; 73:924–930. [PubMed: 23177384]
177. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *JAMA.* 2014; 312:155–161. [PubMed: 25005652]
178. Krishnan-Sarin S, Meandzija B, O'Malley S. Naltrexone and nicotine patch in smoking cessation: A preliminary study. *Nicotine Tob. Res.* 2003; 5:851–857. [PubMed: 14750508]
179. David, SP.; Lancaster, T.; Stead, LF.; Evins, AE.; Prochaska, JJ. *Cochrane Database Syst. Rev.* Vol. 6. John Wiley & Sons, Ltd; 2013. Opioid antagonists for smoking cessation.
180. Ray LA, Miranda R, Kahler CW, Leventhal AM, Monti PM, Swift R, et al. Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. *Psychopharmacology (Berl.).* 2007; 193:449–456. [PubMed: 17484067]
181. King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. *Pharmacol. Biochem. Behav.* 2000; 66:563–572. [PubMed: 10899371]

182. Epstein AM, King AC. Naltrexone attenuates acute cigarette smoking behavior. *Pharmacol. Biochem. Behav.* 2004; 77:29–37. [PubMed: 14724039]
183. Fridberg DJ, Cao D, Grant JE, King AC. Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking. *Alcohol. Clin. Exp. Res.* 2014; 38:2622–2629. [PubMed: 25335648] This secondary analysis of a smoking cessation clinical trial (171) suggested that naltrexone may be more effective in reducing smoking and drinking behavior in heavy drinking smokers than light or nondrinking smokers.
184. O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. *Int. J. Neuropsychopharmacol.* 2009; 12:589–597. [PubMed: 18796184]
185. King A, Cao D, Vanier C, Wilcox T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. *Alcohol. Clin. Exp. Res.* 2009; 33:1044–1050. [PubMed: 19302083]
186. Mattson ME, Litten RZ. Combining treatments for alcoholism: why and how? *J. Stud. Alcohol. Suppl.* 2005:8–16. [PubMed: 16223051]
187. Roche DJO, Bujarski S, Hartwell E, Green R, Ray LA. Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. *Pharmacol. Biochem. Behav.* 2015; 134:92–98. [PubMed: 25933795] This laboratory study in the same sample as 188 demonstrated that the combination of varenicline and naltrexone was more effective than either medication alone and placebo in decreasing smoking intensity as measured by smoking topography.
188. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. *Psychopharmacology (Berl.)*. 2014; 231:3843–3853. [PubMed: 24733235] This laboratory study was the first to report that the combination of varenicline and naltrexone may be more effective than either medication alone and placebo in reducing alcohol and cigarette craving, subjective response, and daily use.
189. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. *Am. J. Drug Alcohol Abuse.* 2015; 41:35–44. [PubMed: 24949564]